Generate Biomedicines, Inc.
GENB
$15.64
$0.614.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -37.67% | -18.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -37.67% | -18.08% | |||
| Cost of Revenue | 7.69% | 23.46% | |||
| Gross Profit | -16.96% | -33.10% | |||
| SG&A Expenses | 28.95% | 33.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.88% | 25.21% | |||
| Operating Income | -19.06% | -33.14% | |||
| Income Before Tax | -18.53% | -39.38% | |||
| Income Tax Expenses | 20.45% | -50.00% | |||
| Earnings from Continuing Operations | -18.53% | -39.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -89.81% | |||
| Net Income | -28.28% | -47.41% | |||
| EBIT | -19.06% | -33.14% | |||
| EBITDA | -20.94% | -34.58% | |||
| EPS Basic | 72.97% | 34.34% | |||
| Normalized Basic EPS | 65.28% | 22.69% | |||
| EPS Diluted | 72.97% | 34.34% | |||
| Normalized Diluted EPS | 65.28% | 22.69% | |||
| Average Basic Shares Outstanding | 288.65% | 97.83% | |||
| Average Diluted Shares Outstanding | 288.65% | 97.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||